Rain Oncology's stock has fallen near 25% following postponement of milademetan's top-line results and increased net losses reported in Q4 2022 and the full year 2022. Investors may be concerned that ...
The Dow Jones closed slightly higher on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in ...
The latest price target for Rain Enhancement (NASDAQ:RAIN) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $1.00 expecting RAIN to fall to within 12 months (a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback